Clinical Trials Logo

Stomach Ulcer clinical trials

View clinical trials related to Stomach Ulcer.

Filter by:

NCT ID: NCT02759224 Completed - Gastric Ulcer Clinical Trials

A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet

Start date: April 15, 2016
Phase: Phase 1
Study type: Interventional

An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers

NCT ID: NCT02752698 Active, not recruiting - Gastric Cancer Clinical Trials

Domestic Surgical Robot Clinical Study

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

Central South University in collaboration with Tianjin University developed the first domestically produced Chinese minimally invasive surgical (MIS) robot system which named "Micro Hand S" in 2013. Recently, as the domestic surgical robot research project's main section, this new MIS robot had been authorized to enter the clinical trial stage by the Ethics Committee of the Third Xiangya Hospital at Central South University.

NCT ID: NCT02710994 Completed - Clinical trials for Gastroesophageal Reflux

Pharmacodynamics and Safety of CDFR0209

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This is a randomized, open-label, two-way crossover study to investigate the pharmacodynamics(24 hour gastric pH) and the safety between repeated doses of CDFR0209 and Losec in Healthy Male Volunteers

NCT ID: NCT02689583 Not yet recruiting - Gastritis Clinical Trials

A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection

Start date: March 2016
Phase: N/A
Study type: Interventional

Since the discovery of Helicobacter pylori (H. pylori), many studies have been carried out with the goal of improving H. pylori eradication and therapies have changed from single-antibiotic treatments to the current multi-antibiotic treatments. However, the eradication rate of H. pylori is still less than 80%. The reasons for this low eradication rate are likely to be multi-factorial, including the reduced activity of antimicrobial drugs, poor patient compliance or micro-environment in stomach. In this study, to obtain the higher eradication of H. pylori and discover the different mechanism between the current infection and refractory infection of H. pylori, it is necessary to perform a prevalence survey for eradication of H. pylori based on the results from isolation of H. pylori strains, antibiotic susceptibility testing, CYP2C19 gene polymorphism, drug resistance gene sequencing and 16SrRNA sequencing.

NCT ID: NCT02423187 Completed - Gastric Ulcer Clinical Trials

Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin

Start date: March 17, 2015
Phase:
Study type: Observational

To investigate the safety and efficacy of long-term combination therapy with rabeprazole and low-dose aspirin.

NCT ID: NCT02299687 Completed - Stomach Ulcer Clinical Trials

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

Start date: September 2014
Phase: Phase 1
Study type: Interventional

A clinical trial to investigate the influence of CYP2C19 polymorphism on pharmacokinetic/pharmacodynamic characteristics of omeprazole in healthy Korean volunteers

NCT ID: NCT02219529 Completed - Chronic Gastritis Clinical Trials

Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases

MCE
Start date: August 2014
Phase: Phase 3
Study type: Interventional

A new Magnetic-controlled Capsule Endoscopy (MCE) was developed by ANKON and got SFDA's approval in China in 2013. It has recently been evaluated to compare the diagnostic accuracy of MCE with that of standard gastroscopy for gastric diseases in 70 patients with encouraging results (In Press). To further testify the diagnostic accuracy of MCE for both the diffuse and focal diseases in stomach, we performed this single-blinded multi-center prospective study compared MCE with gastroscopy in patients with gastric symptoms and indication for upper GI Endoscopy.

NCT ID: NCT02166008 Completed - Clinical trials for Gastric Ulcer Induced by Anti-platelet Agent

Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT

Start date: July 2014
Phase: Phase 2/Phase 3
Study type: Interventional

- Primary objective : To evaluate the efficacy of Rapamide in peptic ulcer prevention in patients taking dual antiplatelet agents - Study Design: Single center, double-blind, randomized-control trial study - Study drug: Repamipide vs. placebo - Assessment criteria The patients will be discharged from the study when one of the followings occurred, 1. Peptic ulcer from upper endoscopy at 3 and 6 month follow up 2. Clinical of upper gastrointestinal bleeding with peptic ulcer from upper endoscopy 3. Anemia by CBC at 1,3 ,6,12 month with peptic ulcer from upper endoscopy 4. Evidence of recurrent myocardial infarction from stent thrombosis

NCT ID: NCT02153398 Completed - Clinical trials for Zollinger-Ellison Syndrome

A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU), non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison syndrome.

NCT ID: NCT02151786 Completed - Clinical trials for Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions

Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

Start date: January 2007
Phase: N/A
Study type: Observational

The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg) to a large number of patients in daily medical practice.